Overview

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Status:
Recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of AKCEA-TTR-LRx compared to placebo for 120 weeks in patients with ATTR-CM receiving available standard of care (SoC). For more information, please visit https://www.cardio-ttransform.com/.

Phase:

Phase 3

Details

Lead Sponsor:

Ionis Pharmaceuticals, Inc.

Collaborator:

Akcea Therapeutics